pfs data support approval of fam-trastuzumab deruxtecan-nxki for her2 breast cancer
Published 4 years ago • 165 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
0:46
clinical trials remain underway for trastuzumab deruxtecan in her2-positive breast cancer
-
8:42
trastuzumab deruxtecan in her2 breast cancer
-
3:50
fda approves fam-trastuzumab deruxtecan-nxki for her2 positive gastric adenocarcinomas
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
7:45
trastuzumab emtansine in her2 breast cancer
-
1:13
dr. hamilton on the efficacy of trastuzumab deruxtecan in her2-low breast cancer
-
3:45
trastuzumab-deruxtecan: a game-changer in her2-positive cancers │ pharmacology
-
2:12
trastuzumab deruxtecan in her2-low advanced breast cancer | nejm
-
7:30
#esmo21 expert video report on her2-positive metastatic breast cancer
-
5:26
trastuzumab deruxtecan shows benefit in patients with her2 mbc
-
3:19
study of targeted therapy for her2-positive metastatic breast cancer
-
30:57
treatment updated for her2 positive breast cancer: changing paradigms
-
4:30
tucatinib for the treatment of her2 breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
5:09
trastuzumab deruxtecan shows benefit across her2 metastatic breast cancer subgroups
-
0:22
targeted therapies for breast cancer: a breakthrough in treatment
-
3:50
herceptin (trastuzumab) for her2-positive breast and stomach cancer